Gum Arabic as Anti-oxidant, Anti-inflammatory and Fetal Hemoglobin Inducing Agent in Sickle Cell Anemia Patients — GA&SCA

Sickle Cell Anemia in Children Clinical Trial

Official title:
Efficacy of Gum Arabic as Anti-oxidant, Anti-inflammatory and Fetal Hemoglobin Inducing Agent in Sickle Cell Anemia Patients : A Randomized, Double-blind, Two-armed Parallel-group, Placebo-controlled Phase II/III Study - Khartoum, Sudan

Status Recruiting

Clinical Trial Summary

To study the efficacy of Gum Arabic as an anti-oxidant, anti-inflammatory and Fetal Hemoglobin-inducing agent among Sickle Cell Disease children. Half of participants will receive Gum Arabic and the other half will receive placebo

Clinical Trial Description

Polymerized hemoglobin is injurious to the red cell membrane, resulting in oxidative damage in sickle cell disease . Fetal hemoglobin is protective against sickling and its decrease is associated with vaso-occlusive crisis . Gum Arabic is soluble fibers with prebiotic properties. It increased the level of serum butyrate which is short chain fatty acid. The latter proved to serve as fetal hemoglobin inducing agent both in vivo and in vitro study. And also has strong anti-inflammatory properties. So our aim to test whether oral digestion of Gum Arabic will induce fetal hemoglobin among sickle cell pediatric patients ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04191213
Study type	Interventional
Source	Al-Neelain University
Contact	Dalya MM Abdelmaged, MBBS
Phone	00249126831595
Email	dalya.alfeel@gmail.com
Status	Recruiting
Phase	Phase 2/Phase 3
Start date	February 15, 2020
Completion date	July 15, 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06387758` - Low Systemic/High Local Exercise Load in Peds SCD	N/A
Completed	`NCT04579926` - PINPOINT: Gaming Technology for SCD Pain	N/A
Completed	`NCT03632876` - Nutritional Outcomes After Vitamin A Supplementation in Subjects With SCD	N/A
Recruiting	`NCT05285917` - Promoting Utilization and Safety of Hydroxyurea Using Precision in Africa	Phase 3
Completed	`NCT04301336` - Different Treatment Modalities in the Management of the Painful Crisis in Pediatric Sickle- Cell Anemia	Phase 2/Phase 3
Completed	`NCT03176849` - A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT	Phase 4
Active, not recruiting	`NCT04750707` - Hydroxyurea Therapy for Neurological and Cognitive Protection in Pediatric Sickle Cell Anemia in Uganda ( BRAINSAFE-II )	Phase 3
Recruiting	`NCT05018728` - The Effect of Voxelotor on Cerebral Hemodynamic Response in Children With Sickle Cell Anemia	Phase 2
Completed	`NCT04844099` - Dihydroartemisinin-Piperaquine or Sulphadoxine-Pyrimethamine for the Chemoprevention of Malaria in Sickle Cell Anaemia	Phase 3
Enrolling by invitation	`NCT03948867` - Stroke Prevention With Hydroxyurea Enabled Through Research and Education (SPHERE)	Phase 2
Completed	`NCT04800809` - The Afolabi Stroke Registry for Children and Young Adults With SCD in Northern Nigeria